SLA Pharma
SLA Pharma is a privately held biopharmaceutical company founded in 1997 that develops and commercializes treatments for gastrointestinal disorders via drug repurposing, operating across the UK, Switzerland, and Ireland through out-licensing and direct product sales.
- Company typePrivate
- Founded1997
- HeadquartersLiestal, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What SLA Pharma does
SLA Pharma is a privately held, founder-controlled biopharmaceutical company founded in 1997 by Justin Slagel, focused exclusively on developing medicines for the prevention and treatment of gastrointestinal and related disorders. Its core technology is a drug repurposing approach that identifies known chemical entities for new pharmacological indications across digestive health, gastrointestinal oncology, proctology, and rare GI disorders. The company states it has over 30 years of clinical trial experience worldwide and positions itself as one of the few global pharmaceutical companies solely dedicated to the GI therapeutic area, with claimed unequalled development, medical, regulatory and commercial expertise and the ability to secure fast-track approvals through novel registration routes.
The company operates through three legal entities — S.L.A Pharma UK Ltd. (registered in England, company number 3370027), SLA Pharma AG (Switzerland), and SLA Pharma IE (Ireland) — with offices in Shenley (UK), Liestal (Switzerland), and Cork (Ireland). Its business model combines direct pharmaceutical product sales of approved human-use products with a capital-light, partnership-driven go-to-market: SLA Pharma monetizes its pipeline and products through out-licensing agreements with pharmaceutical companies for global market access, while simultaneously pursuing in-licensing of assets that align with its GI focus, complemented by collaborations with international research institutions, healthcare providers, and Key Opinion Leaders.
Operationally, SLA Pharma runs a lean organization of 11-50 employees and maintains a minimal external profile (LinkedIn, X/Twitter, corporate website). It has no disclosed external investors, no recorded funding rounds, no M&A activity, and no published revenue figures in the available data, indicating a small, founder-led specialty pharma whose scale and growth are not publicly verifiable from current sources.
SLA Pharma firmographics
Firmographics- Name
- SLA Pharma
- Legal name
- S.L.A Pharma UK Ltd.
- Website
- https://slapharma.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- SLA Pharma is a privately held biopharmaceutical company founded in 1997 that develops and commercializes treatments for gastrointestinal disorders via drug repurposing, operating across the UK, Switzerland, and Ireland through out-licensing and direct product sales.
- Ownership category
- akta.pro rank
SLA Pharma industry classification
Industry- Product category
- Gastrointestinal Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gastroenterology Specialty Pharmaceuticals (HLAIACAE)
- akta.pro secondary industry
- Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)
Keywords
Where SLA Pharma is headquartered
LocationHeadquarters
- HQ city
- Liestal
- HQ country
- Switzerland
- HQ region
- Europe
Offices3 records
Markets served
SLA Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Pharmaceutical Product Sales: SLA Pharma develops and commercializes innovative treatments for gastrointestinal disorders. The company has products in clinical development and already approved for human use.
- Out-Licensing: SLA Pharma partners with trusted pharmaceutical companies to bring innovative gastrointestinal therapies to new markets, providing proven products, regulatory support, and flexible licensing to optimise global market access.
- In-Licensing: SLA Pharma actively seeks in-licensing opportunities aligned with their focus on gastrointestinal and associated conditions, bringing regulatory know-how, commercialisation strength, and global reach to accelerate product development.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
SLA Pharma product offering
Product offeringCore offering
SLA Pharma develops and commercializes pharmaceutical treatments for the prevention and treatment of gastrointestinal and related disorders through a drug repurposing approach—identifying known chemical entities for new pharmacological indications. The portfolio includes products in clinical development as well as products already approved for human use, spanning digestive health, gastrointestinal oncology, proctology, and rare GI disorders. Commercialization is delivered via global out-licensing agreements with pharmaceutical partners and selected in-licensing of GI-aligned assets.
Product overview
SLA Pharma is a niche biopharmaceutical company focused solely on developing medicines for the prevention and treatment of gastrointestinal and related disorders. The company operates across clinical development and commercialization, specializing in identifying known chemical entities for new pharmacological indications (drug repurposing). The product portfolio spans treatments in clinical development as well as products already approved for human use. Core therapeutic focus areas include digestive health, gastrointestinal oncology, proctology, and rare GI disorders. The company maintains over 30 years of clinical trial experience worldwide with global regulatory and commercial expertise. SLA Pharma operates across Europe with offices in the UK (Hertfordshire), Switzerland (Liestal), and Ireland (Cork). No specific named pharmaceutical products or brand names are listed in the source material.
Differentiator
Problem solved
Functional benefit
Products and services
- Gastrointestinal Therapy Portfolio (clinical-stage and approved products) SLA Pharma's gastrointestinal therapy portfolio includes products in clinical development and products already approved for human use, spanning digestive health, gastrointestinal oncology, proctology, and rare GI disorders. The portfolio is developed through a drug-repurposing approach identifying known chemical entities for new pharmacological indications and is delivered to patients worldwide primarily through out-licensing partners.
Quantifiable outcome
- Fast track approvals in global markets through novel registration routes
Companies that use SLA Pharma
Customer profileSegments1 record
Ideal customer profiles2 records
SLA Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
SLA Pharma partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core.
- Renowned ResearcherscorePartnerships with renowned researchers ensure treatments are backed by rigorous scientific validation and drive innovation in gastrointestinal health.
- ClinicianscoreCollaborations with clinicians ensure treatments are grounded in practical medical experience and patient-centered innovation.
- Pharmaceutical OrganisationscorePartnerships with pharmaceutical organisations ensure products are brought to market, with flexible licensing agreements and global distribution support.
- International Research InstitutionscoreSLA Pharma collaborates with International Research Institutions to expedite advanced therapeutic development and expand market reach in gastrointestinal health.
- Healthcare ProviderscoreCollaborations with Healthcare Providers enable SLA Pharma to advance therapeutic development and ensure treatments reach patients worldwide.
- Key Opinion Leaders (KOLs)corePartnerships with Key Opinion Leaders (KOLs) help expedite advanced therapeutic development and provide expert validation for gastrointestinal treatments.
- Out-Licensing PartnerscoreSLA Pharma partners with trusted pharmaceutical companies through out-licensing agreements to bring innovative gastrointestinal therapies to new markets, providing proven products, regulatory support, and global distribution support.
- In-Licensing PartnerscoreSLA Pharma actively seeks in-licensing opportunities aligned with their focus on gastrointestinal and associated conditions, bringing regulatory know-how, commercialisation strength, and global reach to accelerate product development.
Scale indicators3 records
Recent moves5 records
Expansion highlights4 records
SLA Pharma competitors and assessment
Company assessmentMarket position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
SLA Pharma social profiles
Digital presenceSLA Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
SLA Pharma leadership team
Management profileNumber of profiles
Profiles1 record
SLA Pharma subsidiaries and ownership
Company hierarchySubsidiaries2 records
SLA Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SLA Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SLA Pharma
What does SLA Pharma do?
SLA Pharma develops and commercializes pharmaceutical treatments for the prevention and treatment of gastrointestinal and related disorders through a drug repurposing approach—identifying known chemical entities for new pharmacological indications. The portfolio includes products in clinical development as well as products already approved for human use, spanning digestive health, gastrointestinal oncology, proctology, and rare GI disorders. Commercialization is delivered via global out-licensing agreements with pharmaceutical partners and selected in-licensing of GI-aligned assets.
Is SLA Pharma a public or private company?
SLA Pharma is a private company. It is classified as family owned and is currently operating.
When was SLA Pharma founded?
SLA Pharma was founded in 1997. It employs 11 to 50 people.
Where is SLA Pharma based?
SLA Pharma is headquartered in Liestal, Switzerland, in the Europe region.
How does SLA Pharma make money?
Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are out-Licensing and in-Licensing.
Does SLA Pharma have an API?
No public API is recorded for SLA Pharma.
What industry is SLA Pharma in?
SLA Pharma's product category is Gastrointestinal Pharmaceuticals. Its primary akta.pro industry code is HLAIACAE, Gastroenterology Specialty Pharmaceuticals, with a secondary code of HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.